Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Loading...
Embargo End Date
ICR Authors
Authors
Cojocaru, E
Thway, K
Fisher, C
Messiou, C
Zaidi, S
Miah, AB
Benson, C
Gennatas, S
Huang, P
Jones, RL
Thway, K
Fisher, C
Messiou, C
Zaidi, S
Miah, AB
Benson, C
Gennatas, S
Huang, P
Jones, RL
Document Type
Journal Article
Date
2020-12-01
Date Accepted
2020-11-08
Abstract
BACKGROUND/AIM: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma. PATIENTS AND METHODS: We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital. RESULTS: Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months. CONCLUSION: Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.
Citation
Anticancer research, 2020, 40 (12), pp. 7003 - 7007
Source Title
Publisher
INT INST ANTICANCER RESEARCH
ISSN
0250-7005
eISSN
1791-7530
Collections
Research Team
Molecular and Systems Oncology